HCW Biologics EPS Beats, $6.54M Revenue on Licensing Fuel 122% Surge
HCW Biologics reported Q1 2026 EPS of $0.37 versus a $0.44 loss estimate and revenue of $6.54 million, up from $5.06 million year-over-year. Revenue growth was driven by a licensing agreement with Beijing Trimmune that delivered $3.5 million in cash and $3.5 million in equity, though the company faces a 0.09 current ratio and going concern doubts.
1. Q1 2026 Earnings and Revenue
HCW Biologics reported net income of $1.98 million and EPS of $0.37 in Q1 2026, reversing a $2.20 million loss and a $1.97 loss per share in the year-ago quarter. Total revenue rose 29% year-over-year to $6.54 million.
2. Licensing Agreement Details
Revenue growth was led by an exclusive worldwide licensing agreement for HCW11-006 with Beijing Trimmune, generating $3.5 million in nonrefundable cash upfront and $3.5 million in in-kind equity interest.
3. Clinical Trial Progress
The Phase 1 trial of HCW9302 for alopecia areata is underway at two clinical sites, with no dose-limiting toxicities reported to date; a full human data readout is expected in Q4 2026.
4. Financial Position and Risks
As of March 31, 2026, HCW Biologics held $1.72 million in current assets against $19.96 million in current liabilities (0.09 current ratio), plus $6.58 million in short-term debt and $5.76 million in equity, raising substantial doubt about its ability to continue without additional funding.